The proliferation of counterfeit and substandard medicines is a serious threat to public health and a persistent challenge for regulators across the region. Iraq is no exception. The Iraqi legal system addresses this threat through a combination of public health legislation, criminal law, customs enforcement, and intellectual property protection, and a coordinated response across these areas is generally more effective than reliance on any single mechanism.
It is worth distinguishing the two categories at the outset. Counterfeit medicines are products that are deliberately and fraudulently mislabeled with respect to identity, source, or composition, they pretend to be something they are not. Substandard medicines, by contrast, may have been produced without fraudulent intent but fail to meet the quality specifications under which they were authorized. Both categories are illegal in Iraq, and both can cause serious harm ranging from treatment failure to severe adverse reactions and death. From a public health perspective, the harm is similar; from an enforcement perspective, the legal characterization of the conduct, and the available remedies, can differ.
Legal Framework
The principal legal instrument addressing counterfeit medicines is Public Health Law No. 89 of 1981, which prohibits the manufacture, importation, distribution, and sale of unregistered, falsified, expired, or otherwise non-compliant medicines. The Drug Control Law and the ministerial instructions issued under it provide additional detail. The Iraqi Penal Code No. 111 of 1969 applies to fraud, endangerment, and related offenses that frequently accompany counterfeit operations. Where the counterfeit product also infringes registered trademarks or patents, the Trademarks Law No. 21 of 1957 (as amended) and the Patents and Industrial Designs Law No. 65 of 1970 (as amended) provide additional avenues of action.
Criminal penalties under the Public Health Law include substantial fines and imprisonment, with sentences aggravated where the counterfeit product has caused death or serious bodily harm. Liability extends across the supply chain, manufacturer, importer, distributor, retailer, and any individual knowingly involved and corporate entities can face license revocation and closure orders on top of the personal liability of directors and responsible technical staff. The breadth of this liability is intentional: counterfeit networks are rarely the work of a single actor, and the law gives prosecutors the flexibility to pursue everyone who participated in the chain.
Enforcement Authorities
Enforcement is shared between several authorities. Customs, working with the Ministry of Health and the IDCD, has powers to inspect, sample, detain, and seize suspect consignments. The customs interdiction layer has been significantly strengthened in recent years through electronic risk-profiling systems and through cooperation with international counterparts. The Ministry of Health inspectorate conducts routine and targeted inspections of pharmacies, drugstores, hospitals, and clinics, and its inspectors have legal authority to enter premises, examine records, take samples, and seize counterfeit, unregistered, or substandard products. They can also impose immediate suspension of licenses, issue recall orders, and refer cases to the public prosecutor.
Remedies for Rights Holders
For original manufacturers whose products are being counterfeited, the legal system provides several avenues of action. Criminal complaints can be filed with the public prosecutor, and rights holders may also bring civil actions for damages and injunctive relief. Customs complaints can be lodged with supporting evidence to facilitate interdiction. Administrative complaints to the Ministry of Health can trigger investigations and enforcement action. Trademark and patent enforcement is also available before specialized commercial and IP courts. Injunctions, seizure orders, and damages may be obtained where the rights holder presents organized, well-supported evidence of the counterfeit operation.
The practical effectiveness of these remedies depends heavily on the quality of evidence the rights holder can present. We routinely advise manufacturers to invest in proactive measures, authentication features on packaging (holograms, serialization, tamper-evident seals), documentation of the genuine supply chain, market surveillance, retention of samples of encountered counterfeits, and forensic chemical analysis through accredited laboratories. Enforcement actions that arrive at the prosecutor’s office with this kind of evidentiary foundation tend to move quickly; those that arrive as bare allegations tend to languish.
International Cooperation
International cooperation has become increasingly important. The WHO Global Surveillance and Monitoring System for substandard and falsified medical products, Interpol-led cross-border investigations, and bilateral coordination with foreign regulators and law enforcement have all played a role in major cases. This matters in Iraq, because the larger counterfeit operations are rarely purely domestic, products are manufactured outside Iraq and trafficked through informal supply channels, and effective response requires intelligence flowing both ways.
Civil Claims by Patients
Patients harmed by counterfeit or substandard medicines may bring civil actions for damages against manufacturers, distributors, and retailers, subject to the rules on causation and standards of proof under the Iraqi Civil Code. Class actions in the strict sense are not well developed in Iraqi procedure, but multiple individual claims arising from the same incident can be coordinated, and in serious incidents the volume of claims can itself become a meaningful pressure point. Insurance and indemnification across the supply chain should be structured with this in mind.
Preventive Compliance
The legal framework increasingly demands that manufacturers and distributors do more than wait for counterfeits to appear and then react. Serialization at unit level, tamper-evident packaging, and traceability systems are becoming the norm internationally, and electronic tracking is in development in Iraq. Companies operating in Iraq should design their packaging and distribution systems with future electronic traceability requirements in mind, rather than retrofitting them under pressure later.
How We Can Help
Etihad Law Firm represents pharmaceutical companies in both proactive enforcement programs and in specific actions against counterfeiters, including criminal complaints, intellectual property litigation, and customs interdiction. The legal framework provides meaningful tools, but practical effectiveness depends on coordinated action between regulators, customs, law enforcement, and rights holders, and on the quality of preparation that supports each individual case.